Contributions
Abstract: EP1120
Type: E-Poster Presentation
Session title: Myeloproliferative neoplasms - Clinical
Background
The Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), are characterized by clonal proliferation of myeloid–derived hematopoietic stem cells. Patient-reported outcomes (PROs) are an assessment of health outcomes including symptom status, physical function, mental health, social function, and well-being from the patients’ perspective. Besides the life-threatening complications, patients with MPN also suffer from substantial symptom burden, which has aroused great attention in recent years. PROs other than symptom burden such as the impact on work productivity and daily living, satisfaction level with therapy, and health-related quality of life (HRQoL) were also studied in patients with MPN. However, there were limited data of PROs and their associated variables in MPN patients in the developing countries, as most of the published data were from western developed countries, and variables associated with PROs were not fully explored in those studies using multivariate analyses. With different socio-demographic status, financial status, health insurance policy, humanistic philosophy, and treatment pattern, MPN patients in the developing countries might have distinct PROs and different variables associated with them.
Aims
To explore PROs including symptom burden, impact on daily life and work, obstacles during therapy, satisfaction level with therapy, and HRQoL in patients with MPN in China, a representative of developing countries, and to identify variables associated with those PROs.
Methods
A multi-center, cross-sectional study was conducted in patients with MPN across China.
Results
Data from 1,500 respondents including ET (n = 707), PV (n = 316) and MF (n = 477) were analyzed. In multivariate analyses, CALR mutation [HR =0.4 (0.2-0.9); P = 0.020] was significantly-associated with lower MPN-10 scores in respondents with MF. Higher MPN-10 scores were significantly-associated with negative impact on daily life and work as well as lower satisfaction level in those with ET [HR = 3.9 (2.3-6.5); P < 0.001 and HR = 2.1 (1.2-3.9); P = 0.016], PV [HR = 3.2 (1.6-6.5); P = 0.001 and HR = 3.5 (1.4-8.5); P = 0.007] and MF [HR = 2.4 (1.4-4.2); P = 0.002 and HR = 3.9 (2.1-7.5); P < 0.001]. Receiving ruxolitinib was significantly-associated with high satisfaction and satisfaction in respondents with MF [HR = 0.09 (0.03-0.3); P < 0.001]. In addition, demographics and clinical variables including age, gender, household registration, marital status, education level, comorbidity burden, concomitant medication, splenomegaly, complete blood count and annual out-of-pocket costs were also impacting PROs.
Conclusion
Socio-demographic and clinical variables were significantly-associated with PROs in respondents with MPNs.
Keyword(s): Myeloproliferative disorder, Outcome measurement, Ruxolitinib
Abstract: EP1120
Type: E-Poster Presentation
Session title: Myeloproliferative neoplasms - Clinical
Background
The Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), are characterized by clonal proliferation of myeloid–derived hematopoietic stem cells. Patient-reported outcomes (PROs) are an assessment of health outcomes including symptom status, physical function, mental health, social function, and well-being from the patients’ perspective. Besides the life-threatening complications, patients with MPN also suffer from substantial symptom burden, which has aroused great attention in recent years. PROs other than symptom burden such as the impact on work productivity and daily living, satisfaction level with therapy, and health-related quality of life (HRQoL) were also studied in patients with MPN. However, there were limited data of PROs and their associated variables in MPN patients in the developing countries, as most of the published data were from western developed countries, and variables associated with PROs were not fully explored in those studies using multivariate analyses. With different socio-demographic status, financial status, health insurance policy, humanistic philosophy, and treatment pattern, MPN patients in the developing countries might have distinct PROs and different variables associated with them.
Aims
To explore PROs including symptom burden, impact on daily life and work, obstacles during therapy, satisfaction level with therapy, and HRQoL in patients with MPN in China, a representative of developing countries, and to identify variables associated with those PROs.
Methods
A multi-center, cross-sectional study was conducted in patients with MPN across China.
Results
Data from 1,500 respondents including ET (n = 707), PV (n = 316) and MF (n = 477) were analyzed. In multivariate analyses, CALR mutation [HR =0.4 (0.2-0.9); P = 0.020] was significantly-associated with lower MPN-10 scores in respondents with MF. Higher MPN-10 scores were significantly-associated with negative impact on daily life and work as well as lower satisfaction level in those with ET [HR = 3.9 (2.3-6.5); P < 0.001 and HR = 2.1 (1.2-3.9); P = 0.016], PV [HR = 3.2 (1.6-6.5); P = 0.001 and HR = 3.5 (1.4-8.5); P = 0.007] and MF [HR = 2.4 (1.4-4.2); P = 0.002 and HR = 3.9 (2.1-7.5); P < 0.001]. Receiving ruxolitinib was significantly-associated with high satisfaction and satisfaction in respondents with MF [HR = 0.09 (0.03-0.3); P < 0.001]. In addition, demographics and clinical variables including age, gender, household registration, marital status, education level, comorbidity burden, concomitant medication, splenomegaly, complete blood count and annual out-of-pocket costs were also impacting PROs.
Conclusion
Socio-demographic and clinical variables were significantly-associated with PROs in respondents with MPNs.
Keyword(s): Myeloproliferative disorder, Outcome measurement, Ruxolitinib